© 2005 Oxford University Press
ARTICLE |
The Elevated 10-Year Risk of Cervical Precancer and Cancer in Women With Human Papillomavirus (HPV) Type 16 or 18 and the Possible Utility of Type-Specific HPV Testing in Clinical Practice
Affiliations of authors: Hormonal and Reproductive Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, MD (MJK, PEC, SW, M. Sherman, M. Schiffman); Howard Hughes Medical Institute, Chevy Chase, MD (MJK); Digene Corporation, Gaithersburg, MD (ATL); Kaiser Permanente, Portland, OR (DRS, BBR, AGG)
Correspondence to: Philip E. Castle, PhD, MPH, Division of Cancer Epidemiology and Genetics, National Cancer Institute, 6120 Executive Blvd., Rm. 7074, Rockville, MD 20852 (e-mail: castlep{at}mail.nih.gov).
Background: Human papillomavirus (HPV) types 16 and 18 cause 60%–70% of cervical cancer worldwide, and other HPV types cause virtually all remaining cases. Pooled HPV testing for 13 oncogenic types, including HPV16 and 18, is currently used in clinical practice for triage of equivocal cytology and, in conjunction with Pap tests, is an option for general screening among women 30 years of age and older. It is not clear to what extent individual identification of HPV16 or HPV18 as an adjunct to pooled oncogenic HPV testing might effectively identify women at particularly high risk of cervical cancer or its immediate precursor, cervical intraepithelial neoplasia 3 (CIN3). Methods: From April 1, 1989, to November 2, 1990, a total of 20 810 women in the Kaiser Permanente health plan in Portland, OR, enrolled in a cohort study of HPV and cervical neoplasia. Women were tested for 13 oncogenic HPV types by Hybrid Capture 2 (HC2), and those women with a positive HC2 test were tested for HPV16 and 18. Enrollment Pap smear interpretation and HPV test results were linked to histologically confirmed CIN3 and cervical cancer (
CIN3) occurring during 10 years of cytologic follow-up. We calculated cumulative incidence rates with 95% confidence intervals for each interval up to 122 months using Kaplan–Meier methods. Results: The 10-year cumulative incidence rates of CIN3 were 17.2% (95% confidence interval [CI] = 11.5% to 22.9%) among HPV16+ women and 13.6% (95% CI = 3.6% to 23.7%) among HPV18+ (HPV16–) women, but only 3.0% (95% CI = 1.9% to 4.2%) among HC2+ women negative for HPV16 or HPV18. The 10-year cumulative incidence among HC2– women was 0.8% (95% CI = 0.6% to 1.1%). A subanalysis among women 30 years of age and older with normal cytology at enrollment strengthened the observed risk differences. Conclusions: HPV screening that distinguishes HPV16 and HPV18 from other oncogenic HPV types may identify women at the greatest risk of CIN3 and may permit less aggressive management of other women with oncogenic HPV infections.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  J. Koshiol, L. Lindsay, J. M. Pimenta, C. Poole, D. Jenkins, and J. S. Smith Persistent Human Papillomavirus Infection and Cervical Neoplasia: A Systematic Review and Meta-Analysis Am. J. Epidemiol., July 15, 2008; 168(2): 123 - 137. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. E. Castle Invited Commentary: Is Monitoring of Human Papillomavirus Infection for Viral Persistence Ready for Use in Cervical Cancer Screening? Am. J. Epidemiol., July 15, 2008; 168(2): 138 - 144. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L-W Huang, S-L Chao, and B-H Lee Integration of human papillomavirus type-16 and type-18 is a very early event in cervical carcinogenesis J. Clin. Pathol., May 1, 2008; 61(5): 627 - 631. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. C. Rodriguez, M. Schiffman, R. Herrero, S. Wacholder, A. Hildesheim, P. E. Castle, D. Solomon, R. Burk, and On behalf of the Proyecto Epidemiologico Guanacast Rapid Clearance of Human Papillomavirus and Implications for Clinical Focus on Persistent Infections J Natl Cancer Inst, April 2, 2008; 100(7): 513 - 517. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. K. Wong, R. C.-K. Chan, W. S. Nichols, and S. Bose Human Papillomavirus (HPV) in Atypical Squamous Cervical Cytology: the Invader HPV Test as a New Screening Assay J. Clin. Microbiol., March 1, 2008; 46(3): 869 - 875. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Steben Do you approve of spending $300 million on HPV vaccination?: YES Can Fam Physician, February 1, 2008; 54(2): 174 - 176. [Full Text] [PDF]
|
|
|
|
|
|
M. Steben Approuvez-vous les 300 M $ pour la vaccination contre le VPH?: OUI Can Fam Physician, February 1, 2008; 54(2): 178 - 180. [Full Text] [PDF]
|
|
|
|
 |
|
 S. Vinokurova, N. Wentzensen, I. Kraus, R. Klaes, C. Driesch, P. Melsheimer, F. Kisseljov, M. Durst, A. Schneider, and M. von Knebel Doeberitz Type-Dependent Integration Frequency of Human Papillomavirus Genomes in Cervical Lesions Cancer Res., January 1, 2008; 68(1): 307 - 313. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. E. Castle, P. E. Gravitt, D. Solomon, C. M. Wheeler, and M. Schiffman Comparison of Linear Array and Line Blot Assay for Detection of Human Papillomavirus and Diagnosis of Cervical Precancer and Cancer in the Atypical Squamous Cell of Undetermined Significance and Low-Grade Squamous Intraepithelial Lesion Triage Study J. Clin. Microbiol., January 1, 2008; 46(1): 109 - 117. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z. Zhang, I. Borecki, L. Nguyen, D. Ma, K. Smith, P. C. Huettner, D. G. Mutch, T. J. Herzog, R. K. Gibb, M. A. Powell, et al. CD83 Gene Polymorphisms Increase Susceptibility to Human Invasive Cervical Cancer Cancer Res., December 1, 2007; 67(23): 11202 - 11208. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Sokolova, A. Algeciras-Schimnich, M. Song, S. Sitailo, F. Policht, B. R. Kipp, J. S. Voss, K. C. Halling, A. Ruth, W. King, et al. Chromosomal Biomarkers for Detection of Human Papillomavirus Associated Genomic Instability in Epithelial Cells of Cervical Cytology Specimens J. Mol. Diagn., November 1, 2007; 9(5): 604 - 611. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Coutlee, D. Rouleau, G. Ghattas, C. Hankins, S. Vezina, P. Cote, J. Macleod, A. de Pokomandy, D. Money, S. Walmsley, et al. Confirmatory Real-Time PCR Assay for Human Papillomavirus (HPV) Type 52 Infection in Anogenital Specimens Screened for HPV Infection with the Linear Array HPV Genotyping Test J. Clin. Microbiol., November 1, 2007; 45(11): 3821 - 3823. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Jeronimo, L. S. Massad, P. E. Castle, S. Wacholder, M. Schiffman, and for the National Institutes of Health (NIH) Americ Interobserver Agreement in the Evaluation of Digitized Cervical Images Obstet. Gynecol., October 1, 2007; 110(4): 833 - 840. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Dawar MD MHSc, S. Deeks MD MHSc, and S. Dobson MD Human papillomavirus vaccines launch a new era in cervical cancer prevention Can. Med. Assoc. J., August 28, 2007; 177(5): 456 - 461. [Full Text] [PDF]
|
|
|
|
 |
|
 J. K. Chan and J. S. Berek Impact of the Human Papilloma Vaccine on Cervical Cancer J. Clin. Oncol., July 10, 2007; 25(20): 2975 - 2982. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 U. A. Hasan, E. Bates, F. Takeshita, A. Biliato, R. Accardi, V. Bouvard, M. Mansour, I. Vincent, L. Gissmann, T. Iftner, et al. TLR9 Expression and Function Is Abolished by the Cervical Cancer-Associated Human Papillomavirus Type 16 J. Immunol., March 1, 2007; 178(5): 3186 - 3197. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. S. Lea, N. Sunaga, M. Sato, G. Kalahasti, D. S. Miller, J. D. Minna, and C. Y. Muller Silencing of HPV 18 Oncoproteins With RNA Interference Causes Growth Inhibition of Cervical Cancer Cells Reproductive Sciences, January 1, 2007; 14(1): 20 - 28. [Abstract] [PDF]
|
|
|
|
 |
|
 D. Saslow, P. E. Castle, J. T. Cox, D. D. Davey, M. H. Einstein, D. G. Ferris, S. J. Goldie, D. M. Harper, W. Kinney, A.-B. Moscicki, et al. American Cancer Society Guideline for Human Papillomavirus (HPV) Vaccine Use to Prevent Cervical Cancer and Its Precursors CA Cancer J Clin, January 1, 2007; 57(1): 7 - 28. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Kjaer, E. Hogdall, K. Frederiksen, C. Munk, A. van den Brule, E. Svare, C. Meijer, A. Lorincz, and T. Iftner The Absolute Risk of Cervical Abnormalities in High-risk Human Papillomavirus-Positive, Cytologically Normal Women Over a 10-Year Period Cancer Res., November 1, 2006; 66(21): 10630 - 10636. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. T. Hesselink, N. W. J. Bulkmans, J. Berkhof, A. T. Lorincz, C. J. L. M. Meijer, and P. J. F. Snijders Cross-Sectional Comparison of an Automated Hybrid Capture 2 Assay and the Consensus GP5+/6+ PCR Method in a Population-Based Cervical Screening Program. J. Clin. Microbiol., October 1, 2006; 44(10): 3680 - 3685. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. A. T. P. Brink, C. J. L. M. Meijer, M. A. H. M. Wiegerinck, T. E. Nieboer, R. F. P. M. Kruitwagen, F. van Kemenade, N. Fransen Daalmeijer, A. T. Hesselink, J. Berkhof, and P. J. F. Snijders High concordance of results of testing for human papillomavirus in cervicovaginal samples collected by two methods, with comparison of a novel self-sampling device to a conventional endocervical brush. J. Clin. Microbiol., July 1, 2006; 44(7): 2518 - 2523. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Berkhof, N. W.J. Bulkmans, M. C.G. Bleeker, S. Bulk, P. J.F. Snijders, F. J. Voorhorst, and C. J.L.M. Meijer Human papillomavirus type-specific 18-month risk of high-grade cervical intraepithelial neoplasia in women with a normal or borderline/mildly dyskaryotic smear. Cancer Epidemiol. Biomarkers Prev., July 1, 2006; 15(7): 1268 - 1273. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. T. Sandri, P. Lentati, E. Benini, P. Dell'Orto, L. Zorzino, F. M. Carozzi, P. Maisonneuve, R. Passerini, M. Salvatici, C. Casadio, et al. Comparison of the Digene HC2 Assay and the Roche AMPLICOR Human Papillomavirus (HPV) Test for Detection of High-Risk HPV Genotypes in Cervical Samples. J. Clin. Microbiol., June 1, 2006; 44(6): 2141 - 2146. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. R. Kreimer, R. S. Guido, D. Solomon, M. Schiffman, S. Wacholder, J. Jeronimo, C. M. Wheeler, P. E. Castle, and for the ASCUS-LSIL Triage Study (ALTS) Group Human papillomavirus testing following loop electrosurgical excision procedure identifies women at risk for posttreatment cervical intraepithelial neoplasia grade 2 or 3 disease. Cancer Epidemiol. Biomarkers Prev., May 1, 2006; 15(5): 908 - 914. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Grodzki, G. Besson, C. Clavel, A. Arslan, S. Franceschi, P. Birembaut, M. Tommasino, and I. Zehbe Increased Risk for Cervical Disease Progression of French Women Infected with the Human Papillomavirus Type 16 E6-350G Variant. Cancer Epidemiol. Biomarkers Prev., April 1, 2006; 15(4): 820 - 822. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. R. Lowy Human Papillomaviruses: What They Are and What They Do Am. Assoc. Cancer Res. Educ. Book, April 1, 2006; 2006(1): 275 - 278. [Full Text] [PDF]
|
|
|
|
|
|
P. E. Castle, D. Solomon, M. Schiffman, C. M. Wheeler, and for the ALTS Group Human Papillomavirus Type 16 Infections and 2-Year Absolute Risk of Cervical Precancer in Women With Equivocal or Mild Cytologic Abnormalities J Natl Cancer Inst, July 20, 2005; 97(14): 1066 - 1071. [Abstract] [Full Text] [PDF]
|
|